Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer

Genmab A/S (NASDAQ:GMAB) has announced promising new data for its investigational antibody-drug conjugate, rinatabart sesutecan (Rina-S), in advanced endometrial cancer.

Results from the Phase 1/2 RAINFOL-01 trial, presented at the 2025 ASCO Annual Meeting, show that Rina-S 100 mg/m² administered every three weeks achieved a confirmed objective response rate (ORR) of 50%, including two complete responses, in heavily pre-treated patients who had progressed after platinum-based chemotherapy and immune checkpoint inhibitors. The median duration of response was not reached after a median 7.7-month follow-up, indicating sustained benefit for many patients.

A scientist in a lab using a microscope to develop new treatments for Multiple Myeloma.

The trial enrolled 64 patients, with Rina-S also showing anti-tumor activity at 120 mg/m². The safety profile was manageable, with common side effects including diarrhea, fatigue, and nausea, and no cases of ocular toxicity, neuropathy, or interstitial lung disease reported. Serious adverse events occurred in 31.8% of patients at the 100 mg/m² dose. These encouraging results support continued evaluation of Rina-S in ongoing Phase 2 and planned Phase 3 trials, aiming to address the urgent need for new therapies in advanced and recurrent endometrial cancer.

Genmab A/S (NASDAQ:GMAB) is a global biotech company focused on developing innovative antibody therapeutics to improve patient lives. With over 25 years of expertise, GMAB’s team has created advanced antibody platforms, including bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators. Their proprietary pipeline targets cancer and serious diseases, aiming to deliver breakthrough antibody medicines. By 2030, Genmab strives to transform patient care with its next-generation therapies.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.